Condition: Acute Kidney Injury Due to Sepsis · Sponsor: Seoul National University Hospital
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.
This description comes directly from the study's public registry record.
Seung Seok Han, M.D. · 82-2-2072-4785 · hansway7@snu.ac.kr
Donghwan Yun, M.D. · 82-10-9385-6727 · dactylogram@snu.ac.kr
Always discuss trial participation with your own doctor first.
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05575024